Lung Cancer Considered

This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include
WCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul.

Guests:

Myung-Ju Ahn, MD, PhD
Distinguished Professor
Section of Hematology-Oncology, Department of Medicine
Hanyang University Medical Center, Hanyang University School of Medicine
Seoul, Republic of Korea

Vincent Wentao Fang, MD
Professor, Department of Thoracic Surgery
Shanghai East Hospital
Tongji University Medical School

Jiraporn Setakornnukul, MD, PhD
Radiation Oncologist, Associate Professor
Division of Radiation Oncology Department of Radiology
Faculty of Medicine, Siriraj Hospital Mahidol University
Bangkok, Thailand

Yasushi Yatabe, MD, PhD
Chief, Department of Diagnostic Pathology, National Cancer Center Hospital
Chief, Division of Molecular Pathology, National Cancer Center Research Institute
National Cancer Center Japan

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape.

Guests:

Julie R. Brahmer, MD, MSc, FASCO, FAIO
The Marilyn Meyerhoff Professor of Thoracic Oncology
Co-Leader, Cancer Immunology Research Program
Co-Director, Upper Aerodigestive Cancers Program
Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus

Professor Solange Peters, MD, PhD
Chair of Medical Oncology
Director of Oncology Department - CHUV
Lausanne University Hospital

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages.

Guests:
Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care.

Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Natalie Brown and Dr. Aurora Lucas to explore how patients and caregivers are using artificial intelligence in the context of lung cancer care. The discussion highlights real-world experiences, addressing both the benefits of AI in improving understanding and empowerment, and the risks of misinformation, overreliance, and lack of personalization. The conversation also offers practical guidance for patients, families, and clinicians on using AI responsibly while reinforcing the importance of partnership with the care team.

Guests:
Aurora Lucas, EdD
Lung Cancer Patient Advocate

Natalie S. Brown, MBA
Lung Cancer Advocate & Speaker
Founder, Beyond The Diagnosis LLC

As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.

Host: • Alfredo Addeo, MD
Head of Oncology Service
University Hospital Geneva

Guests:
Andrea R. Filippi, MD
Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan
Associate Professor, Radiation Therapy
Department of Oncology, University of Milan

Piergiorgio Solli, MD, PhD
Head of Thoracic Surgery
IRCCS Fondazione Istituto Nazionale dei Tumori, Milan